P harmacological studies of opioid compounds and their chemical analogs in the 1970s led to the identification of several opioid receptor 'subtypes' , one of which was termed the σ receptor 1 . Subsequent pharmacological characterization showed that the σ receptor is distinguished from the true opioid receptors by a divergent ligand binding profile 2, 3 . Later pharmacological studies further divided the receptor into σ 1 and σ 2 subtypes 4 . Molecular cloning of the σ 1 receptor 5 and later the σ 2 receptor 6 showed that these proteins are genetically unrelated to each other and have no similarity to the true opioid receptors. In fact, the σ 1 receptor subtype shows no sequence similarity to any other human protein 5 .
The σ 1 receptor continues to be of pharmacological interest because it binds a host of structurally dissimilar pharmacologically active compounds with high affinity (Fig. 1a ). These compounds include benzomorphans, antipsychotics, psychosis-inducing drugs, the antifungal agent fenpropimorph, sterols such as progesterone, and numerous other compounds 7 . These molecules contain few shared features, although most include a basic nitrogen atom flanked on two sides by longer hydrophobic moieties (typically phenyl rings), representing a minimal σ 1 -binding pharmacophore 8 (Fig. 1a ). The σ 1 receptor's nearest homolog is the yeast Δ 8-Δ 7 sterol isomerase, ERG2p; however, the σ 1 receptor itself has no detectable isomerase activity 5 . Human genetic data have linked point mutations in the σ 1 receptor to inherited motor neuron diseases [9] [10] [11] , and animal models have implicated the receptor in Parkinson's disease 12 , addiction 13 , and pain 14 . A σ 1 receptor antagonist is currently in clinical trials for the treatment of neuropathic pain 15 , and agonists are in clinical trials for Alzheimer's disease 16 and ischemic stroke 17 .
Despite its potential therapeutic relevance and a wealth of highaffinity ligands, surprisingly little is known about the molecular underpinnings of σ 1 receptor function. Substantial evidence suggests that the σ 1 receptor serves as a modulator for other signaling-pathway effectors [18] [19] [20] . Specifically, knockdown or antagonism of the σ 1 receptor can potentiate signaling by G-protein-coupled receptors 18, 19 , whereas agonists of the σ 1 receptor result in enhanced IP3 receptor-dependent intracellular calcium flux 21 and inhibition of sodium-channel 20 and potassium-channel 22, 23 currents. The σ 1 receptor exists in multiple oligomeric states, and reports suggest that agonists cause a shift toward monomeric or low-molecular-weight species, whereas antagonists bias the receptor toward high-molecular-weight species [24] [25] [26] [27] . However, the dominant physiologically relevant oligomeric forms and the precise way in which oligomerization is tied to agonist binding are unknown.
We have recently reported the first structures of the human σ 1 receptor bound to two different ligands, PD 144418, an antagonist, and 4-IBP, a poorly characterized ligand of ambiguous efficacy class 28 . The receptor crystallized as a trimer, and each protomer shows a fold including a single transmembrane domain and a β -barrel flanked by α helices 28 (Fig. 1b,c and Supplementary Fig. 1a ). Although these initial results have provided initial structural information on σ 1 receptor, neither ligand is commonly used to study σ 1 receptor function, and few functional data are available for either ligand.
To understand the molecular basis for agonist activity at σ 1 , we pursued structural studies of three well-characterized classical ligands of the receptor: the antagonists haloperidol and NE-100, and the agonist (+ )-pentazocine. Using the lipidic-cubic-phase method, we determined X-ray crystal structures of the receptor in complex with these three compounds at resolutions of 3.1 Å, 2.9 Å, and 3.1 Å, respectively ( Table 1 and Supplementary Fig. 2 ).
Results
Structure of the human σ 1 receptor bound to antagonists. The structures of the σ 1 receptor bound to the classical antagonists haloperidol and NE-100 are highly similar to each other and to our previously reported structures of σ 1 bound to PD 144418 and 4-IBP 28 ( Supplementary Fig. 1b-e ). Both haloperidol and NE-100 include a shared simple pharmacophore (Fig. 1a) , and both adopt similar conformations in the ligand-binding site ( Fig. 1d, e ). In each case, the ligand's positively charged nitrogen forms an electrostatic interaction with E172, and the rest of the molecule adopts a linear pose that fits within the space not occluded by the many bulky hydrophobic residues that line the interior of the σ 1 binding pocket ( Fig. 1d,e ). In general, the longer of the two hydrophobic regions occupies the region of the β -barrel that is proximal to the membrane, near the space between helices α 4 and α 5 ( The σ 1 receptor is a poorly understood membrane protein expressed throughout the human body. Ligands targeting the σ 1 receptor are in clinical trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain. However, relatively little is known regarding the σ 1 receptor's molecular function. Here, we present crystal structures of human σ 1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+ )-pentazocine, at crystallographic resolutions of 3.1 Å, 2.9 Å, and 3.1 Å, respectively. These structures reveal a unique binding pose for the agonist. The structures and accompanying molecular dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor. Additionally, we show that ligand binding to σ 1 is a multistep process that is rate limited by receptor conformational change. We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes. These data provide a framework for understanding the molecular basis for σ 1 agonism.
Structure of the human σ 1 receptor bound to an agonist. The structures above reveal the overall pose of ligands in the antagonist-bound σ 1 receptor, confirming a highly conserved binding mode and receptor conformation even for chemically diverse antagonists. Next, we investigated the structure of the receptor bound to (+ )-pentazocine at 3.1-Å resolution ( Fig. 2 , Table 1 and Supplementary Fig. 2d ,e). In general, the agonist-bound receptor crystallized similarly to antagonist-bound σ 1 , and the overall conformation of the receptor did not change significantly ( Fig. 2a) . The exception is a movement of helix α 4, which shifts approximately 1.8 Å away from helix α 5 in the (+ )-pentazocine-bound structure relative to the PD 144418-bound structure (Fig. 2b) . This movement appears to be a consequence of the pose adopted by (+ )-pentazocine, which occupies a different portion of the receptor binding pocket than the other ligands examined to date (Fig. 2b,c) . This difference in the position of helix α 4 was also consistently observed in MD simulations (Fig. 2d ). In simulations of ligand-free σ 1 , the helix adopts a position similar to that when an antagonist is bound ( Fig. 2d ), thus also suggesting that the agonist is responsible for the conformational change. (+ )-Pentazocine engages in an electrostatic interaction with E172, and site 2 is positioned similarly to those of the antagonists, but its nonlinear shape forces site 1 to occupy space closer to helix α 4 and further from α 5 relative to the antagonists. To prevent a steric clash between the aromatic ring of (+ )-pentazocine's benzomorphan group and residue A185 in helix α 4 ( Fig. 2c ), helix α 4 must shift toward the membrane and away from the ligand ( Supplementary Fig. 3a ). This movement creates a slightly larger gap between helices α 4 and α 5 in the (+ )-pentazocine-bound structure relative to the antagonist-bound structures. As a result, the distance between helix α 4 and the adjacent protomer shrinks, and in the interface between chains A and C, an electrostatic bond between Q194 in chain C and the backbone of the α 4 helix in chain A is broken ( Supplementary Fig. 3b ). In the two best-resolved protomers of the (+ )-pentazocine-bound structure, chains A and C, two water molecules occupy the space normally occupied by a portion of the antagonist.
A defining feature of σ 1 receptor pharmacology is high selectivity for (+ )-benzomorphans over their (-) enantiomers. It is clear from this structure that (-)-pentazocine would be unable to bind the σ 1 receptor in the same pose as (+ )-pentazocine, because the benzomorphan ring would clash with both Y103 and the receptor backbone ( Supplementary Fig. 3c ). Therefore, (-)-pentazocine must adopt an alternative, presumably higher-energy, conformation to bind the σ 1 receptor.
Although (+ )-pentazocine and other (+ )-benzomorphans are classical σ 1 agonists, other agonists are structurally unrelated. To determine whether other agonists might also place steric pressure on the α 4 helix, we used the Schrödinger Glide package to dock the commonly used agonist PRE-084 into the (+ )-pentazocine-bound σ 1 receptor structure ( Supplementary Fig. 3d ). In its top-ranked pose, PRE-084 adopted a conformation similar to that seen in molecularmodeling simulations performed by Yano et al. 27 , in which one of the carbon rings comes into close contact with the α 4 helix. This pose would be sterically prohibited by the α 4 helix in the antagonistbound structure. Therefore, this conformational change might be broadly important for agonist efficacy among σ 1 receptor ligands. Kinetic analysis of σ 1 receptor ligand association and dissociation. As noted above, the ligand-binding site of the σ 1 receptor is sterically occluded, and so the receptor must undergo a conformational change to allow ligand entry and egress. Previous work has shown that (+ )-pentazocine associates with the receptor slowly 29, 30 , and rate constants have been determined for association and dissociation at a single concentration in guinea pig membranes 30 . To gain a better understanding of how ligands associate and dissociate with the σ 1 receptor, we performed an analysis of ligand binding kinetics by using multiple concentrations of [ 3 H](+ )-pentazocine and membranes prepared from Sf9 cells expressing the human σ 1 receptor. We began by measuring the off rate at 37 °C and found it to follow a slow exponential decay with a half-life longer than 200 min ( Supplementary Fig. 4a ). To obtain detailed association kinetics, we used a scintillation proximity assay (SPA), in which purified FLAGtagged receptor was bound to yttrium silicate SPA beads coated with Protein A and M1 anti-FLAG antibody. In this format, a single reaction can be monitored continuously at room temperature for an extended period ( Supplementary Fig. 4b ). The measured K d in SPA experiments ( Table 2 ) was indistinguishable from that measured in membrane-binding experiments, thus suggesting that the receptor-ligand interaction is similar in both lipid membranes and in detergent ( Supplementary Fig. 4c ). Additionally, the values for these kinetic constants determined by SPA for [ 3 H](+ )-pentazocine association with, and dissociation from, human σ 1 receptor were highly similar to the k obs (0.021 min −1 ) and k off (1.46 × 10 −3 min −1 ) determined by Bowen and colleagues in guinea pig membranes 30 . Unexpectedly, our experiments showed that the association of [ 3 H] (+ )-pentazocine with the σ 1 receptor was not monophasic but was well modeled by a two-step association model, in which a zeroorder reaction, represented by the rate constant k slow , is followed by a concentration-dependent association step, modeled by the rate constant k fast (Fig. 3a-c and Supplementary Fig. 4d ). We also measured ligand dissociation in SPA format. In contrast to the association reaction, the dissociation data fit well to a simple monophasic dissociation curve ( Fig. 3d and Supplementary Fig. 4e ). Interestingly, both the apparent k fast and the k off parameters for [ 3 H](+ )-pentazocine dissociation and association varied nonlinearly with concentration, a result indicative of cooperativity in ligand binding ( Supplementary Fig. 4f ,g and Table 2 ). Additionally, the dissociation curves were clearly nonlinear when plotted in a semilog format, another indication of cooperative binding (Fig. 3d ). However, the Hill coefficient for ligand binding in equilibrium experiments is indistinguishable from 1 ( Supplementary  Fig. 4h ). Therefore, the binding of (+ )-pentazocine to one σ 1 monomer alters the rate of ligand binding to the next monomer but must equally affect both on and off rates. Additionally, although the association curve for each individual concentration could be fit to a twostep exponential function, a simple two-state model is insufficient to account for the global data. These results suggest that though there are at least two steps to ligand association with the σ 1 receptor, there are probably additional steps or conformational states that are not accounted for with a simple two-step fit.
Because the rate-limiting step for [ 3 H](+ )-pentazocine association was not dependent on ligand concentration, we suspected that this step might represent a conformational change from a ligandinaccessible to a ligand-accessible state. To test this hypothesis, we repeated the experiment with [ 3 H]haloperidol. The association of [ 3 H]haloperidol with the σ 1 receptor was also poorly modeled by a one-step reaction but fit well to a two-step model ( Supplementary  Fig. 5a,b) . Additionally, the rate of the slow step was very similar for both [ 3 H]haloperidol and [ 3 H](+ )-pentazocine (Table 2) . Although a t test indicated that the k slow parameter for each ligand was significantly different (P = 0.025), the 95% confidence intervals overlapped, and the difference in the rate constants was relatively small. Given the similarity of the two k slow estimates, and the ability of oligomerization to cause cooperative effects that could influence the rate of conformational changes in ligand-free protomers, we believe these data are consistent with the conclusion that the slow ligandassociation step is a conformational change intrinsic to the receptor that is mostly ligand independent. As seen with [ 3 H](+ )-pentazocine, the dissociation of [ 3 H]haloperidol from the σ 1 receptor was slow and could be modeled by a monophasic exponential-decay function ( Supplementary Fig. 5c,d ).
Ligand binding pathway via molecular dynamics simulation. To better characterize the pathway of ligand binding and dissociation, we performed MD simulations of σ 1 with the goal of characterizing possible conformational rearrangements that could expose the binding pocket. To decrease the computational complexity of the system, we simulated the σ 1 monomer and used accelerated MD, which applies a boost to dihedral energy minima to speed up the observation of conformational changes 31 .
The σ 1 monomer from the crystal structure was inserted into a hydrated lipid bilayer, with (+ )-pentazocine removed from the binding pocket and placed in the water. Using multiple rounds of simulation totaling over 110 μ s, we were able to assemble a threestep binding pathway; (+ )-pentazocine reached a bound state with an r.m.s. deviation < 3 Å to the crystallographic pose (Fig. 4a ).
This binding pathway requires two major conformational rearrangements for the pocket to become accessible to the ligand. First, the 'lid' of the receptor opens, breaking backbone hydrogen bonds between W136 and A161. Next, the β -barrel structure in the interior of the receptor separates, thereby breaking backbone hydrogen bonds between E123 and R175 and exposing the binding pocket. The ligand enters through this opening near the membrane and assumes a near-crystallographic pose as the protein closes around it (Fig. 4b) .
Each of these rare conformational changes or binding events was observed multiple times in simulation. Interestingly, the β -barrel separation that exposes the binding site was observed only in simulations in which the receptor lid had already opened, thus suggesting that two sequential conformational changes may be necessary before the ligand can bind. The lid opening may be a prerequisite for further conformational change, because it may perturb the internal hydrogen-bond network of σ 1 so that larger rearrangements may occur. These conformational changes occur spontaneously and also spontaneously revert in some simulations, thus suggesting that the σ 1 receptor exists in a conformational ensemble of open, ligandaccessible states combined with closed states resembling the crystallographic pose.
Discussion
Antagonism or genetic ablation of the σ 1 receptor has analgesic effects in animals and humans at the whole-body level 14, 15, 32 , and potentiates signaling by G-protein-coupled receptors at the cellular level 18, 19 . In contrast, σ 1 receptor agonists are usually defined by their ability to oppose the effects of antagonists and have been associated with cytoprotective effects [33] [34] [35] . Currently, the biochemical basis for agonism or antagonism at the σ 1 receptor is largely unknown, thereby complicating the unambiguous assignment of efficacy class for σ 1 ligands. The best-documented biochemical difference between the two ligand classes is that antagonists increase the receptor's oligomeric state, whereas agonists decrease the oligomeric state [24] [25] [26] [27] . The structural data presented here show that these ligands occupy a different region of the binding pocket ( Fig. 2c,d) .
Antagonists adopt a more linear pose, with the primary hydrophobic region of the molecule pointing toward the space between helices α 4 and α 5, whereas (+ )-pentazocine's primary hydrophobic site points toward helix α 4 ( Fig. 2c,d) . Presumably, structurally similar agonists such as (+ )-SKF-10,047 adopt a similar pose, thus accounting for their shared biological activities. Indeed, computational docking ( Supplementary Fig. 3d,e ) and modeling 27 suggest that other agonists such as PRE-084 may also preferentially occupy space near helix α 4 relative to antagonists. As a result of the steric constraints of agonists, most of helix α 4 is forced to shift 1.1-1.8 Å away from helix α 5 to accommodate the ligand. In our structure, this shift in α 4 does not disrupt the oligomerization interface between individual protomers. However, if α 4 were to move to a greater degree, it could disrupt the oligomerization interface. This possibility is consistent with prior data suggesting that σ 1 receptor agonists bias the receptor toward lower-molecular-weight states, whereas antagonists bias it toward higher-molecular-weight states [24] [25] [26] [27] . Additionally, molecular modeling by Yano et al. has predicted that (+ )-pentazocine and other multimer-impeding ligands would occupy this space differentially from haloperidol and other multimer-promoting ligands 27 , in agreement with our structural results. Importantly, crystallographic studies by necessity favor conformationally stable, low-energy states, and so the structures shown here may not represent a fully activated state of the receptor. Indeed, studies of G-protein-coupled receptors bound to agonists often show inactive-state structures in the absence of G proteins or antibody-fragment stabilizers 36 .
We also showed by kinetic analysis that (+ )-pentazocine associates with the σ 1 receptor in at least two steps, and MD simulation suggested a three-step process requiring two substantial conformational changes to the receptor. Ligand association and dissociation at the σ 1 receptor is very slow, and the rate-limiting step is independent of ligand concentration. Although many groups have analyzed the effects of σ 1 receptor ligands in cells, there is no standard incubation time for observing σ 1 -dependent effects of σ ligands. A brief survey of the literature revealed that when σ 1 receptor ligands are used in cellular or biochemical assays, incubation times and temperatures vary from room temperature for 20 min (ref. 37 ) to 37 °C for up to 72 h (ref. 35 ). Ligand concentrations are sometimes nearly 10,000-fold greater than the K d [38] [39] [40] . Our data indicate that 1.5 h or more may be required to reach saturation at 37 °C ( Supplementary  Fig. 5f ), and at room temperature, saturation can take nearly a day (Fig. 3a) . Furthermore, because the rate-limiting step is concentration independent, high ligand concentrations cannot overcome the receptor's slow binding kinetics. However, previous reports have shown that σ 1 receptor-dependent effects can be observed in as little as 10 min with 100 nM (+ )-pentazocine at 37 °C, although the effect sizes observed were quite small 41, 42 . This finding is consistent with our data demonstrating that approximately 50% of the receptor population should be occupied under these conditions ( Supplementary Fig. 5f ). Therefore, when ascribing the effects of σ 1 receptor ligands to the σ 1 receptor, researchers must allow sufficient time for the ligands to engage with the receptor, and the signal-tonoise ratio may be improved by longer incubation times. If effects are observed too quickly and are observed only at ligand concentrations vastly higher than the K d , then it is unlikely that the effects are σ 1 mediated. We showed that the agonist (+ )-pentazocine adopts a binding pose in the σ 1 receptor-binding pocket that is different from that of antagonists, which tend to bind similarly to one another despite their chemical diversity. We also demonstrated that ligands associate with the σ 1 receptor very slowly and in multiple steps. Our simulations suggest that ligands enter the binding pocket through a dynamic opening that would be challenging to predict on the basis of a single crystal structure.
The precise details of σ 1 signaling in cells have yet to be determined. Although myriad binding partners for the σ 1 receptor have been proposed 19, 21, 24, 34, 43 , the critical effectors of σ 1 receptor signaling still remain to be unambiguously established. Future work will need to focus on these functional questions to fully understand the function of the σ 1 receptor and its potential as a therapeutic target.
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Methods
Protein expression and purification. Human σ 1 receptor was expressed and purified in Sf9 cells in a manner similar to that described previously 28 . In brief, the receptor was cloned into pFastBac1 with an N-terminal hemagglutinin signal sequence followed by a FLAG epitope tag and a 3 C protease-cleavage site.
The receptor was expressed in Sf9 cells (Expression Systems) with the FastBac baculovirus system (Thermo Fisher). Cells were grown in a shaker at 27 °C and infected when they reached a density of 4 × 10 6 cells/mL. After infection, the cells were allowed to grow for 48-52 h, at which point they were harvested for centrifugation. Pellets were stored at -80 °C until use. For samples used in crystallography, 1 μ M of haloperidol, (+ )-pentazocine, or NE-100 was added to all purification steps. Haloperidol and NE-100 were purchased from Tocris Biosciences, and (+ )-pentazocine was kindly provided by F. Kim. For samples used in SPA binding measurements, no ligand was added. Cell pellets were thawed and lysed by osmotic shock in 20 mM HEPES, pH 7.5, 2 mM MgCl 2 , and 1:200,000 (vol/vol) benzonase nuclease (Sigma Aldrich). The lysate was then spun at 48,000g for 20 min at 4 °C. The supernatant was discarded, and the pellets were solubilized with a glass Dounce tissue homogenizer in a buffer containing 1% (wt/vol) lauryl maltose neopentyl glycol (LMNG, Anatrace), 20 mM HEPES, pH 7.5, 250 mM NaCl, and 20% glycerol. For samples used in the crystallization of σ 1 receptor with haloperidol and (+ )-pentazocine, the solubilization buffer also contained 0.1% (wt/vol) cholesterol hemisuccinate (CHS; Steraloids). However, samples used in the crystallization of σ 1 receptor with NE-100 and in SPA experiments were not solubilized with CHS, because doing so was found to have no effect on protein quality or yield. After homogenization, samples were stirred at 4 °C for 2 h, then centrifuged again as before. The supernatant was filtered over glass microfiber filters, and 2 mM CaCl 2 was added to the solution. The sample was then run over 4 mL of anti-FLAG affinity resin. After the sample was loaded on the resin, it was washed once with 50 mL of buffer containing 0.1% LMNG, 20 mM HEPES, pH 7.5, 150 mM NaCl, 2% glycerol, and 2 mM CaCl 2 , then again with a buffer containing 0.01% LMNG, 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.2% glycerol, and 2 mM CaCl 2 . After these wash steps, the protein was eluted in an identical buffer that lacked CaCl 2 but was supplemented with 0.2 mg/mL FLAG peptide and 5 mM EDTA. Samples used for crystallography were incubated with 3 C protease at 4 °C overnight to remove the FLAG tag. Samples used for SPA experiments were also left at 4 °C overnight but were not digested.
The next day, samples were further purified by SEC on a Sephadex S200 column (GE Healthcare). The buffer for SEC contained 0.01% LMNG, 20 mM HEPES, pH 7.5, and 150 mM NaCl. For samples used for crystallography, the buffer also contained 1 μ M of the desired ligand. After SEC, samples intended for crystallization were concentrated to 25-35 mg/mL and flash frozen in liquid nitrogen in aliquots of 8-9 μ L. Samples intended for SPA experiments were concentrated to 300-400 μ M and diluted to 200 μ M in SEC buffer supplemented with 20% glycerol. The SPA samples were divided into 6-μ L aliquots and flash frozen in liquid nitrogen. All samples were stored at -80 °C and were never frozen again after thawing.
Crystallography and data collection. Purified σ 1 receptor was reconstituted into lipidic cubic phase, as described previously 28, 44 . The cubic phase was dispensed in 30-nL drops onto a hanging-drop cover and overlaid with 600 nL of precipitant solution with a Gryphon LCP robot (Art Robbins Instruments). The crystal that provided the haloperidol-bound structure was grown in 500 mM Li 2 SO 4 , 35% (vol/vol) PEG 300, 1% (vol/vol) hexanediol, and 100 mM MES, pH 6.4. The crystal that provided the (+ )-pentazocine-bound structure was grown in 240 mM Li 2 SO 4 , 42% (vol/vol) PEG 300, 1% (vol/vol) hexanediol, and 0.1 M MES, pH 6.0. The NE-100-bound crystals were grown in 400-500 mM Li 2 SO 4 , 30-40% PEG 300, 1% hexanediol, and 0.1 M MES, pH 5.8-6.0. The crystals grew slowly over the course of 1-3 weeks and were harvested with mesh loops (MiTeGen) and stored at -80 °C. For (+ )-pentazocine-bound crystals, it was important to harvest within 2 weeks to prevent a substantial decline in crystal quality.
Data collection was performed at Advanced Photon Source GM/CA beamlines 23ID-B (NE-100-and (+ )-pentazocine-bound structures) and 23ID-D (haloperidol-bound structure). Data collection was performed as described previously, with a 1.033-Å X-ray wavelength 28 . The datasets for haloperidol-bound and (+ )-pentazocine-bound σ 1 receptor were obtained from single crystals, whereas the dataset for NE-100-bound σ 1 receptor was obtained by merging partial datasets from seven crystals.
Data processing, structure refinement, and model building. Data were processed in XDS 45 . For the haloperidol-and NE-100-bound complexes, scaling was done in XSCALE 45 . For the (+ )-pentazocine-bound structure, scaling was done in Aimless 46 . Phases for all three structures were solved via molecular replacement, with PD144418-bound σ 1 receptor (PDB 5HK1) as a search model. Model building was done in Coot 47 , and refinement was performed in phenix.refine 48 . After refinement, structures were evaluated with MolProbity 49 , and figures were prepared with PyMOL 50 . In the haloperidol-and NE-100-bound structures, 98.3% of the bond angles fall within favorable regions of Ramachandran space, and 1.7% are within the allowed region. For the (+ )-pentazocine-bound structure, 97.7% of the bond angles are within favorable regions of Ramachandran space, and 2.3% are in allowed regions. None of the structures have peptide bonds that are not allowed by Ramachandran statistics. The SBGrid Consortium supported all crystallographic data processing, refinement, and analysis software 51 .
Preparation of membranes for radioligand binding. Membranes were prepared as described previously 52 , with a protocol adapted from Vilner et al. 53 . In brief, Sf9 cells expressing σ 1 receptor were harvested by centrifugation and lysed by osmotic shock in a buffer containing 20 mM HEPES, pH 7.5, 2 mM MgCl 2 ,1:200,000 (vol/vol) benzonase nuclease (Sigma Aldrich), and cOmplete Mini EDTA-free protease-inhibitor tablets (Sigma Aldrich). The lysates were homogenized with a glass Dounce tissue homogenizer and then centrifuged at 48,000g for 20 min. After centrifugation, the membranes were resuspended in buffer containing 50 mM Tris, pH 8.0, and cOmplete Mini EDTA-free protease-inhibitor tablets (Sigma Aldrich). The samples were spun down as before and resuspended in the same buffer. Next, the samples were homogenized with a needle and syringe. Protein content was determined with the DC protein assay (Bio-Rad). Samples were divided into 100-μ L aliquots at protein concentrations of 10-20 mg/mL and flash frozen in liquid nitrogen. All samples were stored at -80 °C until use.
Saturation binding in Sf9 membranes. Saturation binding was performed as described previously 52 , with a method similar to that of Chu and Ruoho 54 . Briefly, membrane samples from Sf9 cells expressing wild-type or mutant σ 1 receptor, prepared as described above, were thawed, homogenized with a syringe, and diluted in 50 mM Tris, pH 8.0. Each reaction was 100 μ L, with a final concentration of 0.025 mg/mL protein and the indicated concentration of [ 3 H](+ )pentazocine. To assay nonspecific binding, equivalent reactions containing 2 μ M haloperidol were performed in parallel. Samples were shaken at 37 °C for 90 min. Afterward, the reaction was terminated by massive dilution and filtration over a glass microfiber filter with a Brandel harvester. Filters were soaked with 0.3% polyethyleneimine for at least 30 min before use. Radioactivity was measured by liquid scintillation counting. Scintillation proximity assay. All SPA experiments were performed with Protein A-coated YSi scintillation proximity beads (PerkinElmer, RPN143). Beads were coupled with M1 anti-FLAG antibody and stored in HBS at 4 °C until use in 5 mg aliquots. Immediately before use, 4-6 mg of beads was spun down twice in a cold centrifuge and resuspended each time in HBS with 0.01% LMNG and 2 mM CaCl 2 . Then, the beads were incubated with 50 nM σ 1 receptor purified as described above for 30 min at 4 °C. After coupling of the receptor, the beads were again centrifuged and resuspended twice in HBS with 0.01% LMNG and 2 mM CaCl 2 . To start the reaction, 40 μ L containing 0.2 mg of receptor-linked beads was added to a solution containing the desired concentration of radioligand in a total volume of 360 μ L, for a total reaction volume of 400 μ L. To assay nonspecific binding, equivalent reactions were prepared that also contained either nonradioactive haloperidol ([ 3 H](+ )-pentazocine binding) or nonradioactive NE-100 ([ 3 H] haloperidol binding) at a concentration of 5 μ M. After association measurements were completed, 5 μ M haloperidol ([ 3 H](+ )-pentazocine binding) or NE-100 ([ 3 H]haloperidol binding) was added to each vial to begin the dissociation measurements. Samples were measured in duplicate at room temperature with a Beckman Coulter LS 6500 multipurpose scintillation counter.
Measurement of ligand dissociation in
To average duplicate points, both the signal in c.p.m. and the time at which the two different vials were measured were averaged. The values for each kinetic constant were first determined for each independent experiment with averaged duplicate time points. Thereafter, the constants from each independent experiment were averaged to obtain a final value with associated errors. s.d. and 95% confidence intervals were determined with only the differences in constants between independent experiments, and did not include error estimates from technical replicates, because the duplicate measures were averaged into single points before calculation of each constant. For all SPA association experiments, the final fits were obtained with k slow constrained to be identical among all concentrations of ligand tested in a given independent experiment. This procedure was done only after we confirmed that all k slow values for a given ligand were statistically indistinguishable with an ANOVA test, because it improved the quality of the fits. Data were analyzed in GraphPad Prism. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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